| ALNYLAM PHARMACE.DL-,0001 |
| USA |
| Gesundheit |
| US02043Q1076 / A0CBCK |
| DUL (Frankfurt) / ALNY (NASDAQ) |
| FRA:DUL, ETR:DUL, DUL:GR, NASDAQ:ALNY |
| - |
| https://www.alnylam.com/ |
|
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company pioneering the development of novel therapeutics based on RNA interference, or RNAi. RNAi represents a natural biological process of gene silencing that enables the creation of a new class o..
>Volltext.. |
| 37518.5 Mio. EUR |
| 37569.25 Mio. EUR |
| 3180.53 Mio. EUR |
| 477.2 Mio. EUR |
| 268.69 Mio. EUR |
| 2.03 EUR |
| 2542.41 Mio. EUR |
| 1419.23 Mio. EUR |
| 448.81 Mio. EUR |
| 1.98 |
| 45.6% |
| - |
| - |
| - |
| - |
| ALNYLAM |
| 08.04.26 |